Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Law MR, Lu CY, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2010 Apr;32(4):729-41; discussion 716. doi: 10.1016/j.clinthera.2010.04.007.

2.

Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.

Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, Ross-Degnan D, Adams AS.

Clin Ther. 2011 Jan;33(1):135-44. doi: 10.1016/j.clinthera.2011.01.012.

3.

Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees.

Adams AS, Zhang F, LeCates RF, Graves AJ, Ross-Degnan D, Gilden D, McLaughlin TJ, Lu C, Trinacty CM, Soumerai SB.

Arch Intern Med. 2009 Apr 27;169(8):750-6. doi: 10.1001/archinternmed.2009.39.

5.

Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.

Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS.

Med Care. 2010 Jan;48(1):4-9. doi: 10.1097/MLR.0b013e3181bd4c10.

PMID:
19956079
6.
7.

Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder.

Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB.

Psychiatr Serv. 2009 Apr;60(4):520-7. doi: 10.1176/appi.ps.60.4.520.

PMID:
19339328
8.

Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

Law MR, Ross-Degnan D, Soumerai SB.

Psychiatr Serv. 2008 May;59(5):540-6. doi: 10.1176/ps.2008.59.5.540.

PMID:
18451014
9.

Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing?

Fischer MA, Choudhry NK, Winkelmayer WC.

Health Aff (Millwood). 2007 May-Jun;26(3):800-7.

PMID:
17485759
10.

The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.

Thamer M, Richard C, Ray NF, Greer JW, Cotter DJ, Pearson BC.

Am J Kidney Dis. 1996 Aug;28(2):235-49.

PMID:
8768919
11.

Impact of race on cumulative exposure to antihypertensive medications in dialysis.

Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Hou Q, Shireman TI.

Am J Hypertens. 2013 Feb;26(2):234-42. doi: 10.1093/ajh/hps019. Epub 2012 Dec 28.

13.

Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.

Amin K, Farley JF, Maciejewski ML, Domino ME.

J Manag Care Spec Pharm. 2017 Mar;23(3):337-345. doi: 10.18553/jmcp.2017.23.3.337.

14.

Differences in the cost of antidepressants across state Medicaid programs.

Kelton CM, Rebelein RP, Heaton PC, Ferrand Y, Guo JJ.

J Ment Health Policy Econ. 2008 Mar;11(1):33-47.

PMID:
18424875
15.

Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.

Pauly NJ, Talbert JC, Brown J.

J Manag Care Spec Pharm. 2016 Jun;22(6):741-51. doi: 10.18553/jmcp.2016.22.6.741.

16.
17.
18.

Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.

Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW.

Clin Ther. 2004 Sep;26(9):1518-32.

PMID:
15531015
19.
20.

Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.

Fischer MA, Cheng H, Schneeweiss S, Avorn J, Solomon DH.

Med Care. 2006 Jul;44(7):658-63.

PMID:
16799360

Supplemental Content

Support Center